Dynavax Technologies Co. (NASDAQ:DVAX) has earned a consensus rating of “Hold” from the eight brokerages that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $27.40.
A number of brokerages have commented on DVAX. Zacks Investment Research downgraded Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. JPMorgan Chase & Co. downgraded Dynavax Technologies from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $31.00 to $25.00 in a research report on Wednesday, February 14th. ValuEngine downgraded Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. BidaskClub upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Monday, February 5th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $27.00 price objective (up previously from $25.00) on shares of Dynavax Technologies in a research report on Thursday, March 8th.
Shares of Dynavax Technologies (NASDAQ DVAX) opened at $16.85 on Tuesday. Dynavax Technologies has a 52 week low of $5.00 and a 52 week high of $24.45. The firm has a market capitalization of $1,020.00, a P/E ratio of -9.11 and a beta of 1.05.
In related news, insider Robert Coffman sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $18.90, for a total transaction of $141,750.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP David Louis Johnson sold 3,092 shares of the firm’s stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $18.60, for a total value of $57,511.20. Following the transaction, the vice president now owns 7,780 shares of the company’s stock, valued at approximately $144,708. The disclosure for this sale can be found here. 2.90% of the stock is currently owned by company insiders.
Institutional investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Dynavax Technologies by 474.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,120 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 5,880 shares during the period. SG Americas Securities LLC bought a new position in shares of Dynavax Technologies during the 3rd quarter worth approximately $287,000. Fox Run Management L.L.C. bought a new position in shares of Dynavax Technologies during the 4th quarter worth approximately $257,000. Legal & General Group Plc lifted its position in shares of Dynavax Technologies by 36.1% during the 3rd quarter. Legal & General Group Plc now owns 17,013 shares of the biopharmaceutical company’s stock worth $365,000 after buying an additional 4,512 shares during the period. Finally, Paloma Partners Management Co bought a new position in shares of Dynavax Technologies during the 4th quarter worth approximately $331,000. Institutional investors and hedge funds own 72.52% of the company’s stock.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.